Overview
A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Status:
Completed
Completed
Trial end date:
2019-10-16
2019-10-16
Target enrollment:
0
0
Participant gender:
All
All
Summary
Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell LymphomaPhase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.Treatments:
Antibodies
Antibodies, Monoclonal
Rituximab
Criteria
Inclusion Criteria:1. CD20-positive B-cell lymphoma.
2. 18 years to 65 years.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
4. Signed an informed consent.
5. Obtained CR (complete remission) or CRu (uncertain complete remission) after the prior
therapy.
Exclusion Criteria:
1. Participation in another interventional clinical trial in the past 28 days.
2. Known allergic reactions against monoclonal antibody or rituximab.
3. Rituximab and other anti-CD20 monoclonal antibody used in the past 4 months.
4. Blood concentration of Rituximab>24ug/ml.
5. HIV positive patients.
6. HCV antigen and antibody positive.
7. Acute and chronic hepatitis B virus infection.